Fundraising Fox

Quoinpharma

Ashburn, US · Founded 2018 · 1 known investors

quoinpharma.com

Quoin Pharmaceuticals is a pharmaceutical company developing therapeutic products for rare diseases, with a lead candidate, QRX003, in clinical trials for Netherton Syndrome. It plans commercial operations in the US, Western Europe, and Japan, supported by international marketing and distribution partnerships across 61 countries.

BiotechHealthtech

Founders & leadership

Quoinpharma was founded in 2018 by Michael Myers, Denise Carter, and MICHAEL MEYERS.

MMMichael Myers
Michael MyersCo-founder
DCDenise Carter
Denise CarterCo-founder
MM
MICHAEL MEYERSCo-founder
SBSally Bridget Lawlor
Sally Bridget LawlorExecutive
EL
Eyal LeibovitzExecutive
SY
Shai YarkoniExecutive

Board

KN
Kasbian Nuriel ChirichBoard director
NL
Natalie LeongBoard director
JC
Joseph CooperBoard director
JC
James CulverwellBoard director
MS
Michael SemberBoard director
DL
Dennis LangerBoard director

Investors · 1

Reported raises · per SEC filings

Form D private placements

$116.5M disclosed across 6 rounds · 2017–2025

$105.3MraisedOct 2025 · 27 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Natalie LeongDirector
  • Michael MyersExecutive Officer, Director
  • Sally Bridget LawlorExecutive Officer
  • Denise CarterExecutive Officer, Director
  • Joseph CooperDirector
  • James CulverwellDirector
  • Michael SemberDirector
  • Dennis LangerDirector
Offering amount
$105.3M
Amount sold
$105.3M
Sales commissions
$1.2M
Placement agents
Maxim Group LLC
First sale
Oct 2025
Incorporated
Corporation, Israel
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$193.5KraisedAug 2022 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • James CulverwellDirector
  • Gordon DunnExecutive Officer
  • Michael SemberDirector
  • Denise CarterExecutive Officer, Director
  • Natalie LeongDirector
  • Michael MyersExecutive Officer, Director
  • Joseph CooperDirector
  • Dennis LangerDirector
Offering amount
$193.5K
Amount sold
$193.5K
First sale
Aug 2022
Incorporated
Corporation, Israel
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$2MraisedApr 2021 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • PETER LANKAUDirector
  • NATALIE LEONGDirector
  • DENISE CARTERExecutive Officer, Director
  • MICHAEL MEYERSExecutive Officer, Director
  • DENNIS LANGERDirector
Offering amount
$22M
Amount sold
$2M
Sales commissions
$945K
Placement agents
JMP SECURITIES LLC
First sale
Mar 2021
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$710KraisedOct 2020 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • MICHAEL MEYERSExecutive Officer, Director
  • PETER LANKAUDirector
  • DENNIS H. LANGERDirector
  • DENISE CARTERExecutive Officer, Director
Offering amount
$3M
Amount sold
$710K
Minimum investment
$100K
First sale
Oct 2020
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$4MraisedFeb 2018 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Yuval BermanDirector
  • Eyal LeibovitzExecutive Officer
  • David BraunDirector
  • Michael BerelowitzDirector
  • Abraham NahmiasDirector
  • Shai YarkoniExecutive Officer, Director
  • Ruth Ben YakarDirector
  • Kasbian Nuriel ChirichDirector
  • Ruhama AvrahamDirector
Offering amount
$4M
Amount sold
$4M
Sales commissions
$280K
Placement agents
H.C. Wainwright & Co., LLC
First sale
Jan 2018
Incorporated
Corporation, Israel
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$4.3MraisedSep 2017 · 18 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Abraham NahmiasDirector
  • Yuval BermanDirector
  • Eyal LeibovitzExecutive Officer
  • Michael BerelowitzDirector
  • David GrossmanDirector
  • Shai YarkoniExecutive Officer, Director
  • Ruth Ben YakarDirector
  • Kasbian Nuriel ChirichDirector
Offering amount
$4.3M
Amount sold
$4.3M
Sales commissions
$85K
Placement agents
H.C. Wainwright & Co., LLC
First sale
Sep 2017
Incorporated
Corporation, Israel
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 5

by search overlap

Companies competing with Quoinpharma for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Quoinpharma do?
Quoin Pharmaceuticals is a pharmaceutical company developing therapeutic products for rare diseases, with a lead candidate, QRX003, in clinical trials for Netherton Syndrome. It plans commercial operations in the US, Western Europe, and Japan, supported by international marketing and distribution partnerships across 61 countries.
Who founded Quoinpharma?
Quoinpharma was founded by Michael Myers, Denise Carter, MICHAEL MEYERS in 2018.
Who are Quoinpharma's investors?
Quoinpharma's investors include Altium Capital.
How much funding has Quoinpharma raised?
Quoinpharma has disclosed $116.5M raised across 6 rounds.
Where is Quoinpharma headquartered?
Quoinpharma is headquartered in Ashburn, US.